Aster Capital Management DIFC Ltd Invests $2.92 Million in Abbott Laboratories $ABT

Aster Capital Management DIFC Ltd acquired a new position in shares of Abbott Laboratories (NYSE:ABT) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 21,796 shares of the healthcare product maker’s stock, valued at approximately $2,919,000. Abbott Laboratories comprises about 1.5% of Aster Capital Management DIFC Ltd’s portfolio, making the stock its 4th largest holding.

A number of other large investors have also added to or reduced their stakes in the company. Cloud Capital Management LLC bought a new position in shares of Abbott Laboratories during the 3rd quarter valued at about $29,000. Guerra Advisors Inc purchased a new stake in Abbott Laboratories in the third quarter worth approximately $31,000. Anfield Capital Management LLC grew its position in Abbott Laboratories by 81.3% during the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after acquiring an additional 104 shares during the last quarter. Delos Wealth Advisors LLC purchased a new position in shares of Abbott Laboratories during the second quarter worth approximately $32,000. Finally, Bridge Generations Wealth Management LLC bought a new stake in shares of Abbott Laboratories in the 3rd quarter worth approximately $33,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on ABT. Leerink Partners reduced their target price on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a report on Friday, January 30th. Raymond James Financial decreased their price objective on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Argus dropped their target price on Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Oppenheimer decreased their price target on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Finally, Citigroup lowered their price target on shares of Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average price target of $137.05.

Insider Activity

In other news, Director Daniel J. Starks acquired 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The shares were bought at an average cost of $108.73 per share, with a total value of $1,087,300.00. Following the transaction, the director owned 6,738,817 shares of the company’s stock, valued at $732,711,572.41. This trade represents a 0.15% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $116.21 on Friday. The company has a current ratio of 1.58, a quick ratio of 1.24 and a debt-to-equity ratio of 0.19. The company’s fifty day moving average price is $117.53 and its 200-day moving average price is $125.41. The stock has a market cap of $201.94 billion, a PE ratio of 31.24, a price-to-earnings-growth ratio of 1.83 and a beta of 0.75. Abbott Laboratories has a 12 month low of $105.27 and a 12 month high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. During the same quarter in the prior year, the company earned $1.34 earnings per share. The business’s revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Analyst/bullish research: A Seeking Alpha piece argues Abbott’s recent pullback is a buying opportunity, citing attractive profitable-growth characteristics and positioning for recovery. Abbott’s Meltdown Is Worth Buying
• Positive Sentiment: Income and steady growth pitch: The Motley Fool highlights Abbott as a steady income stock with double‑digit earnings growth and a dependable dividend, supporting longer-term total‑return appeal. Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time
• Neutral Sentiment: Valuation snapshot shows mixed signals: A Yahoo Finance valuation piece notes short‑term momentum has been weak and longer‑term returns negative, leaving conflicting “fair value” signals for investors to reconcile. Assessing Abbott Laboratories (ABT) Valuation
• Neutral Sentiment: Peer comparison: Coverage comparing Abbott to Intuitive Surgical frames Abbott as the steadier, dividend‑paying medtech pick, while Intuitive may offer higher growth from procedural/robotics expansion — useful for portfolio allocation but not an immediate earnings shock. Intuitive Surgical or Abbott: Which MedTech Stock Is a Better Bet Now?
• Neutral Sentiment: Sector noise from diagnostics peers: A large drop in Grail’s stock after trial updates is creating headline risk for diagnostics names; this may press sentiment in the broader diagnostics/medtech complex but does not directly change Abbott’s fundamentals. Grail’s Stock Dropped 50% on Friday
• Negative Sentiment: Underperformance and analyst skepticism: Multiple pieces note ABT has underperformed the Nasdaq and that some research houses have trimmed price targets and flagged execution/earnings-translation risk — pressure that can weigh on sentiment until clarity on growth drivers. Is Abbott Laboratories Stock Underperforming the Nasdaq?
• Negative Sentiment: Split analyst views driving volatility: A market narrative piece documents a wide range of recent price‑target moves (some cuts, at least one raise into the mid‑$150s), leaving investors with conflicting signals and more volatile price action. How The Evolving Wall Street Narrative Is Reframing Abbott Laboratories (ABT) Valuation Prospects

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.